Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC :

A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.

Related Keywords

United States , Italy , New York , American , Josep Llovet , Riccardo Lencioni , University Of Pisa , American Society Of Clinical Oncology , American Society , Clinical Oncology , Mount Sinai Hospital , Hepatocellular Carcinoma Hcc Liver Cancer Of The , Antiangiogenesis , Angiogenesis Inhibitor , Evacizumab , Humanized Monoclonal Antibody , Rastuzumab Humanised Monoclonal Antibody , Biologic Therapy , Iologics , Vegf , Vascular Endothelial Growth Factor ,